p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer

International Journal of Cancer

Volumn 74, Issue 6, 1997, Pages 605-608

  Dublin, Edwin A ^a   Miles, David W ^a   Rubens, Robert D ^a   Smith, Paul ^a   Barnes, Diana M ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STAINING AND LABELING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031441893     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971219)74:6<605::AID-IJC8>3.0.CO;2-Y     Document Type: Article

References (27)

1. AAS, T., BØRRESEN, A.-L., GEISLER, S., SMITH-SØRENSEN, B., JOHNSEN, H., VARHAUG, J.E., AKSLEN, L.A. and LØNNING, P.E., Specific p53 intitutions are associated with de novo doxorubicin in breast cancer patients. Nature (Med.), 2, 811-814 (1996).
2. BARBARESCHI, M., Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Appl. Immunohistochem., 4, 106-116 (1996).
3. BARNES, D.M., DUBLIN, E.A., FISHER, C.J., LEVISON, D.A. and MILLIS, R.R., Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24, 469-476 (1993).
4. BERGH, J., NORBERG, T., SJÖGREN, S., LINDGREN, A. and HOLMBERG, L., Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature (Med.), 1, 1029-1034 (1995).
5. Cox, D.R., Regression models and life tables. J. roy. Statist. Soc., 84, 1035-1044 (1972).
6. DELIA, D., MIZUTANI, S., LAMORTE, G., GOI, K., IWATE, S. and PIEROTTI, M.A., p53 activity and chemotherapy. Nature (Med.), 2, 724-725 (1996).
7. ELLEDGE, R.M., GRAY, R., MANSOUR, E., YU, Y. CLARK, G.M., RAVDIN, P., OSBORNE, C.K., GILCHRIST, K., DAVIDSON, N.B., ROBERT, N., TOURMEY, D.C. and ALLRED, D.C. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and predinosone for breast cancer. J. nat. Cancer Inst., 87, 1254-1256 (1995).
8. ELSTON, C.W., The assessment of histological differentiation in breast cancer. Austral. N. Zeal. J. Surg., 54, 11-15 (1984).
9. HARTMANN, A., BLASZYK, H., MCGOVERN, R.M., SCHROEDER, J.J., CUNNINGHAM, J., DE VRIES, E.M., KOVACH, J.S. and SUMMER, S.S., p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene, 10, 681-688 (1995).
10. HAWKINS, D.S., DEMERS, G.W. and GALLOWAY, D.A., Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56, 892-898 (1996).
11. HOWELL, A., BUSH, H., GEORGE, W.D., HOWAT, J.M.T., CROWTHER, D., SELLWOOD, R.A., RUBENS, R.D., HAYWARD, J.L., BULBROOK, R.D., FENTIMAN, I.S. and CHAUDARY, M., Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil for breast cancer. Lancet, 2, 307-311 (1984).
12. KAPLAN, E.L. and MEIER, P., Non-parametric estimation from incomplete observations. J. Amer. Statist. Assoc., 53, 457-481 (1958).
13. KING, R.J.B., REDGRAVE, S., HAYWARD, J.L., MILLIS, R.R. and RUBENS, R.D., The measurement of receptors for oestradiol and progesterone in human breast tumors, pp. 55-73, Alpha-Omega, Cardiff, UK (1979).
14. KOECHLI, O.R., SCHAER, G.N., SEIFERT, B., HORNUNG, R., HALLER, U., EPPENBERGER, U. and MUELLER, H., Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet, 344, 1647-1648 (1994).
15. LANE, D.P., p53, guardian of the genome. Nature (Lond.), 358, 15-16 (1992).
16. LANK, D.P., A death in the life of p53. Nature (Lond.), 362, 786-787 (1993).
17. LEE, J.M. and BERNSTEIN, A., p53 mutations increase resistance to ionizing radiation. Proc. nat. Acad. Sci. (Wash.), 90, 5742-5746 (1993).
18. LIEBERMAN, D.A., HOFFMAN, B. and STEINMAN, R.A., Molecular controls of growth arrest and apoptosis: p53 dependent and independent pathways. Oncogene, 11, 199-210 (1995).
19. LOWE, S.W. and JACKS, T., p53 and treatment of bladder cancer: reply. Nature (Lond.), 385, 124-125 (1997).
20. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSMAN, D.E., p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
21. MAKRIS, A., POWLES, T.J., DOWSETT, M. and ALLRED, C., p53 protein overexpression and chemosensitivity in breast cancer. Lancet, 345, 1181-1182 (1995).
22. MATHIEU, M.C., KOSCIELNY, S., LEBIHAN, M.L., SPIELMAN, M. and ARRIAGADA, R., p53 protein overexpression and chemosensitivity in breast cancer. Lancet, 345, 1182 (1995).
23. PETTY, R.D., CREE, I.A., SUTHERLAND, L.A., HUNTER, E.M., LANE, D.P., PREECE, P.E. and ANDREOTTI, P.E., Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem. biophys. Res. Comm., 199, 264-270 (1994).
24. RICHARDS, M.A., O'REILLY, S.M., HOWELL, A., GEORGE, W.D., FENTIMAN, I.S., CHAUDARY, M.A., CROWTHER, D. and RUBENS, R.D., Adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with axillary node positive breast cancer: an update of the Guy's/Manchester trial. J. clin. Oncol., 8, 2032-2039 (1990).
25. STÅL, O., STENMARK, M., ASKMALM, WINGREN, S., RUTQVIST, L.E., SKOOG, L., FERRAUD, L., SULLIVAN, S., CARTENSEN, J. and NORDENSKJOLD, B., p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol., 34, 767-770 (1995).
26. 2/M arrest and apoptosis. Nature (Med.), 2, 72-79 (1996).
27. WU, G.S. and EL-DEIRY, W.S., p53 and chemosensitivity. Nature (Med.), 2, 255-256 (1996).